Success for AMR Global with ‘GLORIA’

AMR-Global has successfully secured co-funding from the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. The program is titled “AMR-Global: Reducinginappropriate exposure to antibiotics” (GLORIA).

AMR-Global is a Netherlands-based public-private partnership (PPP) of which KNCV Tuberculosis Foundation is a partner, that brings together experts in science, business, policy, and society to make feasible, affordable, and necessary solutions to curb antimicrobial resistance (AMR) globally. AMR is an urgent global health problem. Drug-resistant microorganisms already account for a silent pandemic resulting in an estimated 700,000 deaths a yearglobally, a figure that could rapidly increase to 10 million deaths each year by 2050 if no action is taken.  A comprehensive global strategy towards solving AMR is needed to achieve equitable health, which is one of the mainobjectives of the UN Sustainable Development Goals.

The recently awarded GLORIA program aims to reduce and prevent inappropriate exposure to antibiotics, in order to prevent the development of antibiotic resistance, through two lines of research. The Amsterdam Institute for Global Health and Development (AIGHD) and the Amsterdam University Medical Center will lead the first line of research focused on understanding and generating evidence on the impact of rotavirus vaccination (RVV) on antibiotic usage in infants in Africa.

The second line of research entitled BIOBAC (Biomarker driven diagnosis of bacterial infections), is led by Levels Diagnostics, and will develop and test a biomarker panel to distinguish bacterial from viral infection.

These research and innovation initiatives should leverage the Netherlands’ strong position to curb the silent pandemic of AMR, not only to sustain the current low national prevalence status but also from a European and global health perspective.

KNCV has been fighting TB since its establishment in 1903. Over the past 117 years, the organization has acquired indispensable knowledge and experience in the field of effective TB control, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework
Our patroness
Partner with us

Tuberculosis is still one of the major causes of preventable death in the world and claims over 4000 lives a day, leading to over 1,5 million deaths a year.

Patient stories

The story of Abdurahim
The story of Fikeraddis
The story of Issayas
The story of Zarina
The story of Maxine
The story of Saanvi

Address

KNCV Tuberculosefonds
Maanweg 174
2516 AB Den Haag
+31 70 416 7222

OPEN IN GOOGLE MAPS

Postal address

Postbus 146
2501 CC Den Haag

More information

Sorry

De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.